Ann intern med:糖皮质激素可有效治疗肺炎及并发症、死亡率

2015-08-12 sunshine 译 MedSci原创

来自麦克玛斯特大学的一项研究表,皮质类固醇激素在治疗肺炎方面有着很大的优势,该研究成果在线发表于《内科学年鉴》。该研究第一作者Dr. Reed Siemieniuk说道,“我们的研究可导致一个肺炎治疗方案上的重要改变。糖皮质激素廉价且易获得,数以百万的肺炎患者将因我们的研究发现而受益。”世界上,下呼吸道感染是导致新生儿死亡的第二大常见病因。发达国家因社区获得性肺炎而住院的现象十分常见,而且与急性呼


来自麦克玛斯特大学的一项研究表,皮质类固醇激素在治疗肺炎方面有着很大的优势,该研究成果在线发表于《内科学年鉴》。

该研究第一作者Dr. Reed Siemieniuk说道,“我们的研究可导致一个肺炎治疗方案上的重要改变。糖皮质激素廉价且易获得,数以百万的肺炎患者将因我们的研究发现而受益。”

世界上,下呼吸道感染是导致新生儿死亡的第二大常见病因。发达国家因社区获得性肺炎而住院的现象十分常见,而且与急性呼吸窘迫综合征的发生有关,需要机械通气治疗,其死亡率极高。
来自麦克玛斯特大学的研究人员与多个国际合作者共同进行了此研究,研究纳入了2000余名患者,进行了13次随机对照试验。

研究结果显示,接受糖皮质激素治疗的社区获得性肺炎患者出院要早一天。糖皮质激素的应用减少了5-9%的患者对机械通气(或呼吸管)的需求;同时还减少了2-8%的患者发生急性呼吸窘迫综合征的危险。研究结果还显示,糖皮质激素的应用还可使患者的死亡率从10%大大降低至6%。

“我们很难看到和社区获得性肺炎一样普遍的疾病在治疗上取得重大进步,”Dr. Gordon Guyatt说道,“短期内糖皮质激素的应用是安全的,而且我们现已知道糖皮质激素可在治疗一种常见且严重的内科疾病上发挥重要的作用。”

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1701131, encodeId=bbea1e0113196, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Thu Aug 27 12:01:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757665, encodeId=75f61e576652e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Oct 12 16:01:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600235, encodeId=6e431600235e1, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Fri Aug 14 03:01:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606567, encodeId=9232160656edd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 14 03:01:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619414, encodeId=2073161941488, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Aug 14 03:01:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1701131, encodeId=bbea1e0113196, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Thu Aug 27 12:01:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757665, encodeId=75f61e576652e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Oct 12 16:01:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600235, encodeId=6e431600235e1, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Fri Aug 14 03:01:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606567, encodeId=9232160656edd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 14 03:01:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619414, encodeId=2073161941488, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Aug 14 03:01:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]
    2015-10-12 丁鹏鹏
  3. [GetPortalCommentsPageByObjectIdResponse(id=1701131, encodeId=bbea1e0113196, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Thu Aug 27 12:01:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757665, encodeId=75f61e576652e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Oct 12 16:01:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600235, encodeId=6e431600235e1, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Fri Aug 14 03:01:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606567, encodeId=9232160656edd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 14 03:01:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619414, encodeId=2073161941488, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Aug 14 03:01:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1701131, encodeId=bbea1e0113196, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Thu Aug 27 12:01:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757665, encodeId=75f61e576652e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Oct 12 16:01:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600235, encodeId=6e431600235e1, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Fri Aug 14 03:01:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606567, encodeId=9232160656edd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 14 03:01:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619414, encodeId=2073161941488, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Aug 14 03:01:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1701131, encodeId=bbea1e0113196, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Thu Aug 27 12:01:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757665, encodeId=75f61e576652e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Oct 12 16:01:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600235, encodeId=6e431600235e1, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Fri Aug 14 03:01:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606567, encodeId=9232160656edd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 14 03:01:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619414, encodeId=2073161941488, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Aug 14 03:01:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]

相关资讯

J Dent Res:睡觉时佩戴假牙可增加老年人患肺炎的风险

J Dent Res:睡觉时佩戴假牙可增加老年人患肺炎的风险越来越多人意识到不良的口腔卫生是老年人肺炎的主要危险因素。为了确定多种口腔健康相关的危险因素,我们采用了前瞻性研究以评估社区老年人群(年龄在85岁及以上)中一系列的口腔健康行为与肺炎发生率之间可能存在的关系。研究开始随机选择了524名老年人(228名男性和296名女性;平均年龄为87.8岁),检查各研究对象的口腔卫生状况,记录其口腔健康行

PD-1抗体,疗效虽好,但也要担心肺炎副作用

特别提醒使用PD1抗癌的患者注意可能的副作用-肺炎,临床试验中出现了因肺炎致死的病例,尤其是有肺部病史的非小细胞肺癌患者,出门的时候最好戴口罩,防止感染。我们总结了PD1抗体临床试验中肺炎发生的情况和日本的《PD1使用指南》中肺炎的发生和处理方法,以及一部分具体实例供参考,希望能帮到大家。 PD1临床试验中现肺炎副作用出现的比例 4月19号的《新英格兰医学杂志》发表的关于使用默克的PD

AJRCCM:对大环内酯类耐药不能证明肺炎患者预后不佳

背景:关于使用大环内酯类药物在治疗肺炎链球菌肺炎疾病时,患者的临床表现和预后至今在许多研究中尚存在争议。研究方式:我们在西班牙巴塞罗那所有医院中进行了一项回顾性、观察性的研究,研究对象是2000年1月1日到2013年12月31日诊所内所有肺炎链球菌培养结果阳性的成年住院患者。我们观察的主要指标包括患者发生菌血症、肺部并发症、急性肾功能衰竭、休克、转入ICU、需要呼吸机辅助通气的患者人数及比例,此外

Lancet:接受适当初始抗生素治疗的肺炎患者的30天死亡率风险因素分析

    适当的初始抗生素治疗感染性疾病是必不可少的。然而,尽管接受适当的初始抗生素治疗,一些肺炎的患者仍然可能会出现不利的结果。该研究的目的是明确在接受适当的初始抗生素治疗的患者30天的死亡率的风险因素,并确定受益于辅助治疗潜在的候选人。    从2010年3月15日至12月22日,研究人员在十家医疗机构对因肺炎入院的患者(年龄≥20岁)做了一项前瞻性观察研

AJRCCM:十年间社区获得性肺炎(CAP)的死亡率研究

社区获得性肺炎(CAP)的长期预后研究数据是有限的。本研究观察了社区获得性肺炎(CAP)的十年死亡率并探讨CAP是否会增加长期不良结局。 在2000-2002年间,研究人员收纳了来自加拿大6家医院和7个急诊科的6078例CAP患者,以及收纳了与年龄、性别和治疗地点相匹配的5个非肺炎人群的对照组(n=29402)。通过调整社会经济地位和合并症,使用多变量Cox比例风险分析评估了到2012年的死亡率

NEJM:多糖+疫苗对抗肺炎球菌肺炎

背景 肺炎球菌多糖结合疫苗预防婴幼儿肺炎球菌疾病,但他们对65岁及以上成年人或老年人社区获得性肺炎的疗效是未知的。 方法 在一项随机,双盲,安慰剂对照试验,涉及84496名65岁或以上成年人,我们评估了13价多糖结合疫苗(PCV13)有效预防肺炎球菌疫苗株的第一次社区获得性肺炎,菌血症性和非侵入性肺炎球菌肺炎和侵袭性肺炎球菌疾病。标准的实验室方法和血清型特异性尿抗原检测用来确定社区获得性肺炎和